IP Library Granted Patent US 8,017,791
Granted Patent B2
US 8,017,791 · App. 12/050,040 · Granted Sep 13, 2011

Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives

Assignee: Wayne State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,791
App. No.
12/050,040
Granted
Sep 13, 2011
Kind
B2
Abstract

Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.

Claims (36)

1. A compound having formula X:

or a pharmaceutically acceptable salt thereof, wherein:

A and A′ are individually selected from the group of optionally substituted C 4 -C 14 aryl and heteroaryl wherein heteroatoms of heteroaryl A and/or A′ are selected from the group consisting of O, N, and S;

Z is a chemical bond or —Y—(CH 2 ) o ;

Y is NH or O;

o is 0, 1, 2, 3, or 4;

and

W 3 is an alkyl amine or an aryl amine.

2. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof, wherein:

m and n are 0-4;

Z is a chemical bond or —Y—(CH 2 ) o —;

Y is NH or O;

o is 0, 1, 2, 3, or 4;

at least one of A and A′ are selected from the group consisting of:

p is 0-6;

R 1 is C 1-4 alkyl, C 2-6 alkenyl, C 2-6 optionally halogenated alkynyl, C 2-6 hydroxyalkynyl, halo, —CN, —COOR 4 , —OH, —NO 2 , —NH 2 , —NHR 4 , —SO 2 NH 2 , —NHSO 2 R 8 , —OCF 3 , or —OR 8 ;

R 2 has the meaning of R 1 or a 5 or 6 membered heterocycle containing 1 or more heteroatoms selected from the group consisting of N, O, and S;

X 2 is N, O, or S;

R 4 is H, C 1-18 alkyl, C 5-10 cycloalkyl, or C 2-18 alkylene;

R 8 is C 1-8 alkyl, C 5-6 cycloalkyl, C 2-8 alkenyl, or a 5 or 6-member aromatic ring including heterocyclic rings;

B is selected from the group consisting of:

3. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof, wherein:

m and n are 0-4;

Z is selected from the group consisting of a chemical bond and —Y—(CH 2 ) o ;

Y is NH or O;

o is 0, 1, 2, 3, or 4;

at least one of A and A′ are selected from the group consisting of:

p is 0-6;

R 1 is C 1-4 alkyl, C 2-6 alkenyl, C 2-6 optionally halogenated alkynyl, C 2-6 hydroxyalkynyl, halo, —CN, —COOR 4 , —OH, —NO 2 , —NH 2 , —NHR 4 , —SO 2 NH 2 , —NHSO 2 R 8 , —OCF 3 , or -Ole;

R 2 has the meaning of R 1 or a 5 or 6 membered heterocycle containing 1 or more heteroatoms selected from the group consisting of N, O, and S;

X 2 is N, O, or S;

R 4 is H, C 1-18 alkyl, C 5-10 cycloalkyl, or C 2-18 alkylene; and

R 8 is C 1-8 alkyl, C 5-6 cycloalkyl, C 2-8 alkenyl, or a 5 or 6-member aromatic ring including heterocyclic rings; and

B is selected from the group consisting of:

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 30, 2012
From: WAYNE STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028669/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: DUTTA, ALOKE K.
To: WAYNE STATE UNIVERSITY
Reel/Frame 022648/0790 →
Continuity (5)
Continuation In Part 11330972 · Jan 12, 2006
Continuation In Part PCTUS2005012748 · Apr 15, 2005
Continuation In Part 10311796 · Mar 28, 2003
Provisional Application 60563189 · Apr 16, 2004
Related Publication 20080167478A1 · Jul 10, 2008